The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Franco Maggiolo

Division of Infectious Diseases

Unit of Antiviral Therapy

Ospedali Riuniti

Largo Barozzi 1

Italy

[email]@hotmail.com

Name/email consistency: high

 
 
 
 
 
 
 

Affiliation

  • Division of Infectious Diseases, Unit of Antiviral Therapy, Ospedali Riuniti, Largo Barozzi 1, Italy. 2000 - 2009

References

  1. CD4 cell-guided scheduled treatment interruptions in HIV-infected patients with sustained immunologic response to HAART. Maggiolo, F., Airoldi, M., Callegaro, A., Martinelli, C., Dolara, A., Bini, T., Gregis, G., Quinzan, G., Ripamonti, D., Ravasio, V., Suter, F. AIDS (2009) [Pubmed]
  2. Efavirenz: a decade of clinical experience in the treatment of HIV. Maggiolo, F. J. Antimicrob. Chemother. (2009) [Pubmed]
  3. Efavirenz. Maggiolo, F. Expert. Opin. Pharmacother (2007) [Pubmed]
  4. Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI- or PI-treated patients. Maggiolo, F., Airoldi, M., Kleinloog, H.D., Callegaro, A., Ravasio, V., Arici, C., Bombana, E., Suter, F. HIV. Clin. Trials (2007) [Pubmed]
  5. Resistance costs and future drug options of antiretroviral therapies: analysis of the role of NRTIs, NNRTIs, and PIs in a large clinical cohort. Maggiolo, F., Ripamonti, D., Airoldi, M., Callegaro, A., Arici, C., Ravasio, V., Bombana, E., Goglio, A., Suter, F. HIV. Clin. Trials (2007) [Pubmed]
  6. Reasons for discontinuation of nevirapine-containing HAART: results from an unselected population of a large clinical cohort. Maggiolo, F., Arici, C., Airoldi, M., Ripamonti, D., Quinzan, G., Gregis, G., Ravasio, V., Bombana, E., Suter, F. J. Antimicrob. Chemother. (2007) [Pubmed]
  7. The effect of HIV-1 resistance mutations after first-line virological failure on the possibility to sequence antiretroviral drugs in second-line regimens. Maggiolo, F., Ripamonti, D., Torti, C., Arici, C., Antinori, A., Quiros-Roldan, E., Minoli, L., Sighinolfi, L., Nasta, P., Suter, F. Antivir. Ther. (Lond.) (2006) [Pubmed]
  8. Quadruple-drug induction HAART in advanced HIV infection. Maggiolo, F., Ripamonti, D., Callegaro, A., Gregis, G., Quinzan, G., Suter, F. HIV. Clin. Trials (2005) [Pubmed]
  9. Switch strategies in patients on effective HAART. Maggiolo, F., Ripamonti, D., Suter, F. J. Antimicrob. Chemother. (2005) [Pubmed]
  10. Salvage therapy with abacavir in HIV-1-infected patients with previously documented M184V mutation: a possibility of NRTI recycling. Maggiolo, F., Callegaro, A., Arici, C., Quinzan, G., Gregis, G., Ripamonti, D., Tebaldi, A., Goglio, A., Suter, F. Antivir. Ther. (Lond.) (2003) [Pubmed]
  11. Once-a-day HAART: dream or reality?. Maggiolo, F., Ripamonti, D., Suter, F. HIV. Clin. Trials (2003) [Pubmed]
  12. Outcome of 2 simplification strategies for the treatment of human immunodeficiency virus type 1 infection. Maggiolo, F., Ripamonti, D., Ravasio, L., Gregis, G., Quinzan, G., Callegaro, A., Arici, C., Suter, F. Clin. Infect. Dis. (2003) [Pubmed]
  13. Once-a-day therapy for HIV infection: a controlled, randomized study in antiretroviral-naive HIV-1-infected patients. Maggiolo, F., Ripamonti, D., Gregis, G., Quinzan, G., Callegaro, A., Arici, C., Ravasio, L., Suter, F. Antivir. Ther. (Lond.) (2003) [Pubmed]
  14. Simpler regimens may enhance adherence to antiretrovirals in HIV-infected patients. Maggiolo, F., Ripamonti, D., Arici, C., Gregis, G., Quinzan, G., Camacho, G.A., Ravasio, L., Suter, F. HIV. Clin. Trials (2002) [Pubmed]
  15. Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz. Maggiolo, F., Migliorino, M., Maserati, R., Pan, A., Rizzi, M., Provettoni, G., Rizzi, L., Suter, F. Antivir. Ther. (Lond.) (2001) [Pubmed]
  16. In-vitro activity of moxifloxacin combined with other antibacterials against methicillin-resistant Staphylococcus aureus. Maggiolo, F., Capra, R., Bottura, P., Pravettoni, G., Migliorino, M., Suter, F. J. Chemother (2000) [Pubmed]
 
WikiGenes - Universities